Data show five-year response for AAT deficiency gene therapy

June 7, 2017

Data demonstrating sustained protein expression five years after a single intramuscular injection of a gene-based therapy for the treatment of alpha-1 antitrypsin (AAT) deficiency also shows improvements in multiple indicators of AAT biological activity. The study appears in the June issue of Molecular Therapy. Applied Genetic Technologies Corporation (AGTC), a clinical stage biopharmaceutical company, developed the gene-based therapy evaluated in the study, which was led by Terence R. Flotte, MD, the Celia and Isaac Haidak Professor of Medical Education, executive deputy chancellor, provost and dean of the School of Medicine, and colleagues at UMass Medical School.

AAT deficiency is an inherited genetic defect that results in severe loss of lung function. The study describes five-year follow-up results of a one-time intramuscular injection of a recombinant adeno-associated virus (AAV)-AAT vector in patients with AAT deficiency who had participated in a Phase 2a trial and had not received subsequent AAT .

Key findings from the study include:

  • Sustained expression of AAT protein over the five-year study period without re-administration of AAV-AAT vector and in the absence of or ;
  • Partial correction of disease-associated defects in neutrophils, a type of immune cell that contributes to lung damage in patients with AAT, including neutrophil elastase inhibition, markers of degranulation and membrane-bound anti-neutrophil antibodies;
  • Evidence of an active regulatory T-cell response that contributed to stable gene expression despite the presence of an immune response directed against the AAV vector; and
  • Continuous, steady-state levels of AAT protein without the peak and trough effects observed following infusion of AAT protein replacement therapy.

"This is the first publication to demonstrate multi-year persistence of recombinant AAV expression in gene therapy trial participants without immune suppression or corticosteroid therapy," Dr. Flotte said. "We also observed specific regulatory T-cell responses directed against AAV1 capsid proteins, and believe that these responses may help the immune system become tolerant to AAV1. This would be beneficial in enabling the development of AAV-based therapies for AAT deficiency that provide durable responses following a single administration and may also allow for repeat dosing regimens with potential to improve long-term outcomes for patients with AAT deficiency."

The authors conclude that stable levels of serum AAT achieved in this study over five years may have beneficial clinical effects, despite being below the threshold of what is traditionally considered therapeutic. They hypothesize that continuous expression at a lower level may provide greater clinical benefit compared with levels that fluctuate drastically, as is observed with current AAT replacement therapy.

Explore further: What causes gene transfer to trigger T cell activation and exhaustion?

More information: Christian Mueller et al. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency, Molecular Therapy (2017). DOI: 10.1016/j.ymthe.2017.03.029

Related Stories

What causes gene transfer to trigger T cell activation and exhaustion?

April 27, 2017
Researchers are beginning to gain a clearer understanding of how the immune system responds, in both a reactive and tolerant way, to gene therapy delivered using what has become the preferred gene delivery vector, adeno-associated ...

Debate continues over human immune system's role in blocking therapeutic genes delivered using AAV vectors

April 5, 2017
The hypothesis that memory T cells formed in response to childhood infections may be to blame for the loss of expression of therapeutic genes delivered via viral vectors has been hotly debated, but recent clinical trials ...

Does the body's immune response to viral vector delivery systems affect the safety or efficacy of gene therapy?

January 8, 2014
Packaging replacement genes in viruses is an effective method to deliver them to target tissues, but the human body mounts an immune response against the virus. The systemic and local immune reactions induced by an adeno-associated ...

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors

December 30, 2016
Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the ...

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

March 31, 2017
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward ...

Will AAV vectors have a role in future novel gene therapy approaches?

March 20, 2017
Recombinant adeno-associated virus (rAAV) vectors for delivering therapeutic genes have demonstrated their safety in multiple diseases and clinical settings over the years and are a proven and effective tool that can be used ...

Recommended for you

Genome analysis with near-complete privacy possible, say researchers

August 17, 2017
It is now possible to scour complete human genomes for the presence of disease-associated genes without revealing any genetic information not directly associated with the inquiry, say Stanford University researchers.

Science Says: DNA test results may not change health habits

August 17, 2017
If you learned your DNA made you more susceptible to getting a disease, wouldn't you work to stay healthy?

Genetic variants found to play key role in human immune system

August 16, 2017
It is widely recognized that people respond differently to infections. This can partially be explained by genetics, shows a new study published today in Nature Communications by an international collaboration of researchers ...

Phenotype varies for presumed pathogenic variants in KCNB1

August 16, 2017
(HealthDay)—De novo KCNB1 missense and loss-of-function variants are associated with neurodevelopmental disorders, with or without seizures, according to a study published online Aug. 14 in JAMA Neurology.

Active non-coding DNA might help pinpoint genetic risk for psychiatric disorders

August 16, 2017
Northwestern Medicine scientists have demonstrated a new method of analyzing non-coding regions of DNA in neurons, which may help to pinpoint which genetic variants are most important to the development of schizophrenia and ...

Evolved masculine and feminine behaviors can be inherited from social environment

August 15, 2017
The different ways men and women behave, passed down from generation to generation, can be inherited from our social environment - not just from genes, experts have suggested.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.